Retatrutide Dose Calculation from Reconstituted Vial
When you reconstitute 12 mg of retatrutide powder in 2 mL of sterile water, the resulting concentration is 6 mg/mL; therefore, a 0.1 mL injection delivers exactly 0.6 mg of retatrutide.
Concentration Calculation
- The reconstituted vial contains 12 mg of retatrutide in a total volume of 2 mL, yielding a concentration of 6 mg per mL (12 mg ÷ 2 mL = 6 mg/mL). 1
Dose Delivered by 0.1 mL Injection
- A 0.1 mL injection from this 6 mg/mL solution delivers 0.6 mg of retatrutide (0.1 mL × 6 mg/mL = 0.6 mg). 1
Clinical Context for a 140-lb (63.5 kg) Adult Female
- In the phase 2 obesity trial, retatrutide was administered as once-weekly subcutaneous injections with maintenance doses ranging from 1 mg to 12 mg. 1
- The 0.6 mg dose you calculated falls below the lowest studied maintenance dose (1 mg) and would be considered a sub-therapeutic dose based on current clinical trial data. 1
- Dose escalation protocols in the phase 2 trials typically started at 2 mg or 4 mg for the first dose, then escalated to maintenance doses of 4 mg, 8 mg, or 12 mg to balance efficacy with gastrointestinal tolerability. 1, 2
Practical Dosing Guidance
- If your goal is to administer a starting dose of 2 mg, you would need to inject 0.33 mL from the reconstituted vial (2 mg ÷ 6 mg/mL = 0.33 mL). 1
- For a 4 mg dose, inject 0.67 mL (4 mg ÷ 6 mg/mL = 0.67 mL). 1
- For an 8 mg dose, inject 1.33 mL (8 mg ÷ 6 mg/mL = 1.33 mL). 1
- For a 12 mg dose, inject 2.0 mL (the entire vial contents). 1
Safety and Tolerability Considerations
- Gastrointestinal adverse events (nausea, vomiting, diarrhea) are dose-related and occur most frequently during the initial weeks of therapy; starting with a lower initial dose (2 mg) and escalating over 4–8 weeks partially mitigates these effects. 1, 2
- In the phase 2 obesity trial, dose-dependent increases in heart rate (up to 6.7 beats per minute) peaked at 24 weeks and declined thereafter; this effect should be monitored in patients with cardiovascular risk factors. 1, 3
- No severe hypoglycemia or deaths were reported in the phase 2 trials, and most adverse events were mild to moderate in severity. 2
Common Pitfalls to Avoid
- Do not assume that a 0.1 mL injection represents a therapeutic dose; always calculate the exact milligram amount based on your reconstitution concentration. 1
- Do not use household measuring devices; employ a calibrated 1 mL or 3 mL syringe with 0.1 mL graduations for accurate subcutaneous dosing. 4
- Do not skip dose escalation in treatment-naïve patients; abrupt initiation at high doses (8 mg or 12 mg) significantly increases the risk of gastrointestinal side effects. 1, 2